Publications by authors named "Alessandra Di Liello"
Article Synopsis
- Small cell lung cancer (SCLC) is a fast-growing lung cancer type that responds well to certain treatments, but not all patients benefit, highlighting a need for new therapies and biomarkers.
- The study investigated how exosomes from the blood of SCLC patients can influence responses to chemoimmunotherapy by examining immune and tumor markers.
- Results showed that exosomes from patients who responded well to treatment significantly increased cancer cell death in lab tests, suggesting they could help understand the interaction between cancer and the immune system.
Article Synopsis
- Lung cancer (both non-small cell and small cell types) is currently treated with a mix of chemo- and immunotherapy, but effective biomarkers for predicting patient responses are needed.
- The study focuses on the cGAS-STING pathway in peripheral blood mononuclear cells (PBMCs) to identify treatment responses in lung cancer patients, revealing that better responders had significantly higher levels of STING and CXCL10.
- Results suggest that activating the cGAS-STING signaling in PBMCs could serve as a novel predictor for immunotherapy response, with higher levels indicating better treatment outcomes and enhanced anti-tumor immune activity.
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
Int J Cancer
October 2023
The randomized phase II VELO trial showed that the addition of panitumumab to trifluridine/tipiracil significantly improves progression-free survival (PFS) as compared to trifluridine/tipiracil in third-line therapy in patients with refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC). With longer follow-up, final overall survival results and posttreatment subgroup analysis are presented. Sixty-two patients with refractory RAS WT mCRC were randomly assigned to receive, as third-line therapy, trifluridine/tipiracil alone (arm A) or in combination with panitumumab (arm B).
View Article and Find Full Text PDFPanitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
JAMA Oncol
July 2023
Importance: Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-type (WT) MCRC may be valuable for these patients.
Objective: To compare the anti-EGFR monoclonal antibody panitumumab plus standard-of-care trifluridine-tipiracil with trifluridine-tipiracil alone as third-line therapy for RAS WT MCRC.
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.
Cancers (Basel)
April 2023
Article Synopsis
- * Among 129 patients, 97 had WT circulating tumor DNA (ctDNA) while 32 had mutated ctDNA, with similar median anti-EGFR drug-free intervals between groups (10.6 months for mutants vs. 13.0 months for WT).
- * Results indicate that the duration of being free from anti-EGFR drugs alone isn't a reliable way to choose patients for treatment, highlighting the importance of using liquid biopsies for better treatment outcomes.
Importance: Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment with cetuximab plus avelumab with overall survival (OS) may be worthy of investigation in this setting.
Objective: To assess the efficacy and safety of cetuximab rechallenge therapy plus avelumab.
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience.
Cancers (Basel)
October 2019
Tumor heterogeneity represents a possible cause of error in detecting predictive genetic alterations on tumor tissue and can be overcome by testing alterations in circulating tumor DNA (ctDNA) using liquid biopsy. We assessed 72 consecutive patients with a diagnosis of metastatic colorectal cancer (mCRC) using Idylla™ Biocartis, a fully automated platform that evaluates the most frequent mutations of KRAS, NRAS and BRAF genes. We correlated the results of liquid biopsy and standard tissue-based next generation sequencing (NGS) analyses to patient clinical features.
View Article and Find Full Text PDF